Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon α-2b and ribavirin

Oxidative stress modulation in hepatitis C virus infected cells

“…Based on the multiple oxidant and antioxidant activities performed in vivo and in vitro systems during viral infections, and the variable ability of antioxidants to cross cell membranes, the systematic use of antioxidants as antiviral therapies had been limited [40] . On the other hand, HCV is potentially lymphotropic, because it can invade and propagate in cells of the [47,48] 400-544 IU/d or 600 mg 1 Vitamin C [48] 500 mg-10 g N-acetylcysteine [78] 600 mg or 1800 mg/d 1 Mitoquine Q [65,66] 40 or 80 mg/d α-tocopherol [79] 600 mg, 500 mg/d, 800 IU/d Glycyrrhizin [40,42,53,54] 500 mg, 120 mg Different mechanisms Silymarin (Silibinin A, Silibinin B, etc.) [40,64,[80][81][82] 250 mg or 5-20 mg/kg 1 S-adenosylmethionine [69] 1600 mg/d 1 Acetylsalicylic acid [73] 4 mmol/L (in vitro) Gallic acid 300 mg/mL (in vitro) 1 Combined treatment with interferon.…”

“…von Herbay et al [47] reported that vitamin E decreases the hepatic aminotransferase levels in patients whit chronic HCV infection. Murakami et al [48] observed that antioxidant vitamins (E and C) supplemented during interferon alpha treatment inhibited the decrease in eicosapentaenoic acid of mononuclear cell. They also stated that it might be possible to enhance the efficacy of combination therapy of interferon alfa-2b and RBV [48] .…”

“…Murakami et al [48] observed that antioxidant vitamins (E and C) supplemented during interferon alpha treatment inhibited the decrease in eicosapentaenoic acid of mononuclear cell. They also stated that it might be possible to enhance the efficacy of combination therapy of interferon alfa-2b and RBV [48] . There are other reports, with conflicting or nonreproducible results, so there is still controversy on their usefulness.…”

Serum fatty acids, antioxidants, and treatment response in hepatitis C infection: Greater polyunsaturated fatty acid and antioxidant levels in hepatitis C responders

“…18 In liver diseases, an appropriate balance between n-6 and n-3 PUFAs may be protective 19 and has been an indicator of effective IFR treatment in terms of liver enzyme normalization. 7 Antioxidants can influence the chain-reaction of PUFA peroxidation. Thorlaksdottir et al 20 reported a positive correlation of plasma AOX with the proportion of total The group type (responders, nonresponders, untreated, healthy controls) had a significant main effect upon all 12 serum fatty acids on the basis of group differences for STE, AA, and EPA.…”

“…4 Also, a possible diminishing effect of PUFAs on liver inflammation has been suggested. 5 In CHC therapy, PUFAs inhibited HC virus replication 6 or facilitated interferon-a (IFR-a) treatment, 7 resulting in liver enzyme normalization. In the course of an IFR-a therapy, the FA desaturation is altered as well.…”